Cargando…
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Massachusetts Medical Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342381/ https://www.ncbi.nlm.nih.gov/pubmed/35857646 http://dx.doi.org/10.1056/NEJMc2207519 |
| _version_ | 1784760813777584128 |
|---|---|
| author | Takashita, Emi Yamayoshi, Seiya Simon, Viviana van Bakel, Harm Sordillo, Emilia M. Pekosz, Andrew Fukushi, Shuetsu Suzuki, Tadaki Maeda, Ken Halfmann, Peter Sakai-Tagawa, Yuko Ito, Mutsumi Watanabe, Shinji Imai, Masaki Hasegawa, Hideki Kawaoka, Yoshihiro |
| author_facet | Takashita, Emi Yamayoshi, Seiya Simon, Viviana van Bakel, Harm Sordillo, Emilia M. Pekosz, Andrew Fukushi, Shuetsu Suzuki, Tadaki Maeda, Ken Halfmann, Peter Sakai-Tagawa, Yuko Ito, Mutsumi Watanabe, Shinji Imai, Masaki Hasegawa, Hideki Kawaoka, Yoshihiro |
| author_sort | Takashita, Emi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9342381 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Massachusetts Medical Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93423812022-08-01 Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants Takashita, Emi Yamayoshi, Seiya Simon, Viviana van Bakel, Harm Sordillo, Emilia M. Pekosz, Andrew Fukushi, Shuetsu Suzuki, Tadaki Maeda, Ken Halfmann, Peter Sakai-Tagawa, Yuko Ito, Mutsumi Watanabe, Shinji Imai, Masaki Hasegawa, Hideki Kawaoka, Yoshihiro N Engl J Med Correspondence Massachusetts Medical Society 2022-07-20 /pmc/articles/PMC9342381/ /pubmed/35857646 http://dx.doi.org/10.1056/NEJMc2207519 Text en Copyright © 2022 Massachusetts Medical Society. All rights reserved. http://www.nejmgroup.org/legal/terms-of-use.htm This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
| spellingShingle | Correspondence Takashita, Emi Yamayoshi, Seiya Simon, Viviana van Bakel, Harm Sordillo, Emilia M. Pekosz, Andrew Fukushi, Shuetsu Suzuki, Tadaki Maeda, Ken Halfmann, Peter Sakai-Tagawa, Yuko Ito, Mutsumi Watanabe, Shinji Imai, Masaki Hasegawa, Hideki Kawaoka, Yoshihiro Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants |
| title | Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants |
| title_full | Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants |
| title_fullStr | Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants |
| title_full_unstemmed | Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants |
| title_short | Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants |
| title_sort | efficacy of antibodies and antiviral drugs against omicron ba.2.12.1, ba.4, and ba.5 subvariants |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342381/ https://www.ncbi.nlm.nih.gov/pubmed/35857646 http://dx.doi.org/10.1056/NEJMc2207519 |
| work_keys_str_mv | AT takashitaemi efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT yamayoshiseiya efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT simonviviana efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT vanbakelharm efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT sordilloemiliam efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT pekoszandrew efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT fukushishuetsu efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT suzukitadaki efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT maedaken efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT halfmannpeter efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT sakaitagawayuko efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT itomutsumi efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT watanabeshinji efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT imaimasaki efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT hasegawahideki efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants AT kawaokayoshihiro efficacyofantibodiesandantiviraldrugsagainstomicronba2121ba4andba5subvariants |